Roche bags full con­trol of Foun­da­tion Med­i­cine in $2.4B fol­low-up buy­out

What­ev­er Foun­da­tion Med­i­cine has been do­ing since Roche threw its weight be­hind an R&D col­lab­o­ra­tion three years ago, both part­ners are lik­ing it. And now, Roche wants all of it, putting $2.4 bil­lion more on the ta­ble.

The val­u­a­tion of Cam­bridge, MA-based Foun­da­tion has grown quite a bit since Roche ac­quired a ma­jor­i­ty stake in Jan­u­ary 2015 at $50 a share — a hefty pre­mi­um then — with each share now cost­ing the Swiss phar­ma gi­ant $137. That’s 29% more than its clos­ing price on Mon­day. Roche’s as­sess­ment of the com­pa­ny val­ue: $5.3 bil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER